In the course of the Oct 2013 NOPR general public Conference, As well as in subsequent penned comments, stakeholders offered input regarding general problems pertinent to the rulemaking, including the trial typical levels and proposed normal concentrations presented, the rulemaking timeline, the metrics used to normalize equipment size, and various